Spots Global Cancer Trial Database for Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
Official Title: A Phase II Trial of Thalidomide in Patients With Relapsed Chronic Lymphocytic Leukemia
Study ID: NCT00006226
Study Description
Brief Summary: Phase II trial to study the effectiveness of thalidomide in treating patients who have relapsed chronic lymphocytic leukemia. Thalidomide may stop the growth of chronic lymphocytic leukemia by stopping blood flow to the tumor.
Detailed Description: PRIMARY OBJECTIVES: I. To determine whether thalidomide can induce objective responses in relapsed B-CLL patients. II. To determine the toxicity of thalidomide in this patient population. III. To document if alterations in vascular growth factors and/or bone marrow angiogenesis patterns correlate with thalidomide related clinical responses. OUTLINE: Patients receive oral thalidomide daily for 4 weeks. Courses repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 5 years.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
North Central Cancer Treatment Group, Rochester, Minnesota, United States
Contact Details
Name: Neil Kay
Affiliation: North Central Cancer Treatment Group
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
